These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 18381901

  • 1. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study.
    Gründer G, Fellows C, Janouschek H, Veselinovic T, Boy C, Bröcheler A, Kirschbaum KM, Hellmann S, Spreckelmeyer KM, Hiemke C, Rösch F, Schaefer WM, Vernaleken I.
    Am J Psychiatry; 2008 Aug; 165(8):988-95. PubMed ID: 18381901
    [Abstract] [Full Text] [Related]

  • 2. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.
    Kegeles LS, Slifstein M, Frankle WG, Xu X, Hackett E, Bae SA, Gonzales R, Kim JH, Alvarez B, Gil R, Laruelle M, Abi-Dargham A.
    Neuropsychopharmacology; 2008 Dec; 33(13):3111-25. PubMed ID: 18418366
    [Abstract] [Full Text] [Related]

  • 3. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
    Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S.
    Am J Psychiatry; 2007 Sep; 164(9):1411-7. PubMed ID: 17728427
    [Abstract] [Full Text] [Related]

  • 4. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
    Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF.
    Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
    Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G.
    Am J Psychiatry; 2004 May; 161(5):818-25. PubMed ID: 15121646
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography.
    Kegeles LS, Slifstein M, Xu X, Urban N, Thompson JL, Moadel T, Harkavy-Friedman JM, Gil R, Laruelle M, Abi-Dargham A.
    Biol Psychiatry; 2010 Oct 01; 68(7):634-41. PubMed ID: 20673873
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder.
    Potkin SG, Keator DB, Kesler-West ML, Nguyen DD, van Erp TG, Mukherjee J, Shah N, Preda A.
    CNS Spectr; 2014 Apr 01; 19(2):176-81. PubMed ID: 24073841
    [Abstract] [Full Text] [Related]

  • 12. The relationship between excitement symptom severity and extrastriatal dopamine D2/3 receptor availability in patients with schizophrenia: a high-resolution PET study with [18F]fallypride.
    Joo YH, Kim JH, Son YD, Kim HK, Shin YJ, Lee SY, Kim JH.
    Eur Arch Psychiatry Clin Neurosci; 2018 Sep 01; 268(6):529-540. PubMed ID: 28623450
    [Abstract] [Full Text] [Related]

  • 13. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia.
    Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, Shi B, Mantil J, Kemether E, Oakes TR, Mukherjee J.
    Schizophr Res; 2006 Jul 01; 85(1-3):232-44. PubMed ID: 16713185
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride.
    Mukherjee J, Christian BT, Narayanan TK, Shi B, Mantil J.
    Neuropsychopharmacology; 2001 Oct 01; 25(4):476-88. PubMed ID: 11557161
    [Abstract] [Full Text] [Related]

  • 17. New insights into clinical response in schizophrenia: from dopamine D2 receptor occupancy to patients' quality of life.
    Goff DC.
    Am J Psychiatry; 2008 Aug 01; 165(8):940-3. PubMed ID: 18676595
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Calculating occupancy when one does not have baseline: a comparison of different options.
    Kim E, Howes OD, Yu KS, Jeong JM, Lee JS, Jang IJ, Shin SG, Kapur S, Kwon JS.
    J Cereb Blood Flow Metab; 2011 Aug 01; 31(8):1760-7. PubMed ID: 21522162
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study.
    Mallikaarjun S, Kane JM, Bricmont P, McQuade R, Carson W, Sanchez R, Forbes RA, Fleischhacker WW.
    Schizophr Res; 2013 Oct 01; 150(1):281-8. PubMed ID: 23890595
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.